ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

28-year old female at 20 weeks' gestation… Total resection of the tumor was performed (Figure 1B) with histopathological diagnose of GBM (Figure 1C)....But BRAF V600E mutation was detected Table 3, showing targeted therapy with BRAF inhibitor may bring benefits for the patient. Thus, vemurafenib was applied...Follow-up MRI showed stable disease with no recurrence in the right parietal area (Figure 1G). It has been more than 2 years from the initiation of the multidisciplinary therapy to the latest follow-up examination. The life quality of the patient was satisfied with a healthy baby in the meantime.

We describe the pediatric case of a now 12 year old Caucasian male who originally presented at age 9 with a right fronto-parietal glioblastoma multiforme that recurred 2 ½ years from diagnosis. Molecular analysis of the primary tumor revealed a BRAF V600E mutation and the patient was placed on the BRAF inhibitor vemurafenib. A complete response was observed after 4 months of therapy and remains sustained at 6 months.